Iñigo Angulo-Barturen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Iñigo Angulo-Barturen has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Teresa Mulet
ID CEDD Diseases of the Developing World, GlaxoSmithKline, c/Severo Ochoa 2, 28760, Tres Cantos, Spain,1 The Jackson Laboratory, 600 Main Street, Bar Harbor, Maine 046092
4 shared publicationsSara Viera
GlaxoSmithKline, Diseases of the Developing World-Tres Cantos Medicines Development Campus, Tres Cantos 28760, Madrid, Spain
3 shared publicationsDomingo Gargallo-Viola
ID CEDD Diseases of the Developing World, GlaxoSmithKline, c/Severo Ochoa 2, 28760, Tres Cantos, Spain,1 The Jackson Laboratory, 600 Main Street, Bar Harbor, Maine 046092
2 shared publicationsDomingo Gargallo‐Viola
GlaxoSmithKline R & D, ID CEDD Diseases of the Developing World, Tres Cantos, Spain
2 shared publicationsJoaquín Rullas
Diseases of the Developing World, Infectious Diseases-Centre for Excellence in Drug Discovery (ID CEDD), GlaxoSmithKline, Tres Cantos, Madrid, Spain
2 shared publicationsMaría Belén Jiménez-Díaz
GlaxoSmithKline, Diseases of the Developing World-Tres Cantos Medicines Development Campus, Tres Cantos 28760, Madrid, Spain
2 shared publications
Latest Publications
- Open Access
- 5 November 2015
- Published by Springer Nature in Malaria Journal
- Vol. 14 (1) , 1-8
Identifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assay
The emergence of Plasmodium falciparum resistance to artemisinins threatens to undermine the effectiveness of artemisinin-based combination anti-malarial therapy. Developing suitable drugs to replace artemisinins requires the identification of new compounds that display rapid parasite killing kinetics. However, no current methods fully meet the requirements to screen large compound libraries for candidates with such properties. This study describes the development and validation of an in vitro parasite viability fast assay for identifying rapidly parasiticidal anti-malarial drugs. Parasite killing kinetics were determined by first culturing unlabelled erythrocytes with P. falciparum in the presence of anti-malarial drugs for 24 or 48 h. After removing the drug, samples were added to erythrocytes pre-labelled with intracellular dye to allow their subsequent identification. The ability of viable parasites to re-establish infection in labelled erythrocytes could then be detected by two-colour flow cytometry after tagging of parasite DNA. Thus, double-stained erythrocytes (with the pre-labelled intracellular dye and the parasite DNA dye) result only after establishment of new infections by surviving parasites. The capacity of the test anti-malarial drugs to eliminate viable parasites within 24 or 48 h could, therefore, be determined. The parasite viability fast assay could be completed within 48 h following drug treatment and distinguished between rapidly parasiticidal anti-malarial drugs versus those acting more slowly. The assay was validated against ten standard anti-malarial agents with known properties and results correlated well with established methods. An abbreviated assay, suitable for adaption to medium–high throughput screening, was validated and applied against a set of 20 compounds retrieved from the publically available Medicines for Malaria Venture ‘Malaria Box’. The quantification of new infections to determine parasite viability offers important advantages over existing methods, and is amenable to medium–high throughput screening. In particular, the parasite viability fast assay allows discrimination of rapidly parasiticidal anti-malarial candidates.
- 5 November 2015
- Published by Springer Nature in Malaria Journal
- Vol. 14 (1) , 1-8
Open AccessIdentifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assay
The emergence of Plasmodium falciparum resistance to artemisinins threatens to undermine the effectiveness of artemisinin-based combination anti-malarial therapy. Developing suitable drugs to replace artemisinins requires the identification of new compounds that display rapid parasite killing kinetics. However, no current methods fully meet the requirements to screen large compound libraries for candidates with such properties. This study describes the development and validation of an in vitro parasite viability fast assay for identifying rapidly parasiticidal anti-malarial drugs. Parasite killing kinetics were determined by first culturing unlabelled erythrocytes with P. falciparum in the presence of anti-malarial drugs for 24 or 48 h. After removing the drug, samples were added to erythrocytes pre-labelled with intracellular dye to allow their subsequent identification. The ability of viable parasites to re-establish infection in labelled erythrocytes could then be detected by two-colour flow cytometry after tagging of parasite DNA. Thus, double-stained erythrocytes (with the pre-labelled intracellular dye and the parasite DNA dye) result only after establishment of new infections by surviving parasites. The capacity of the test anti-malarial drugs to eliminate viable parasites within 24 or 48 h could, therefore, be determined. The parasite viability fast assay could be completed within 48 h following drug treatment and distinguished between rapidly parasiticidal anti-malarial drugs versus those acting more slowly. The assay was validated against ten standard anti-malarial agents with known properties and results correlated well with established methods. An abbreviated assay, suitable for adaption to medium–high throughput screening, was validated and applied against a set of 20 compounds retrieved from the publically available Medicines for Malaria Venture ‘Malaria Box’. The quantification of new infections to determine parasite viability offers important advantages over existing methods, and is amenable to medium–high throughput screening. In particular, the parasite viability fast assay allows discrimination of rapidly parasiticidal anti-malarial candidates.
- Open Access
- 14 April 2014
- Published by Springer Nature in Malaria Journal
- Vol. 13 (1) , 143
Repositioning: the fast track to new anti-malarial medicines?
Repositioning of existing drugs has been suggested as a fast track for developing new anti-malarial agents. The compound libraries of GlaxoSmithKline (GSK), Pfizer and AstraZeneca (AZ) comprising drugs that have undergone clinical studies in other therapeutic areas, but not achieved approval, and a set of US Food and Drug Administration (FDA)-approved drugs and other bio-actives were tested against Plasmodium falciparum blood stages.
- 14 April 2014
- Published by Springer Nature in Malaria Journal
- Vol. 13 (1) , 143
Open AccessRepositioning: the fast track to new anti-malarial medicines?
Repositioning of existing drugs has been suggested as a fast track for developing new anti-malarial agents. The compound libraries of GlaxoSmithKline (GSK), Pfizer and AstraZeneca (AZ) comprising drugs that have undergone clinical studies in other therapeutic areas, but not achieved approval, and a set of US Food and Drug Administration (FDA)-approved drugs and other bio-actives were tested against Plasmodium falciparum blood stages.
- 21 June 2013
- Published by Cambridge University Press (CUP) in Parasitology
- Vol. 141 (1) , 93-103
Animal models of efficacy to accelerate drug discovery in malaria
SUMMARY: The emergence of resistance to artemisinins and the renewed efforts to eradicate malaria demand the urgent development of new drugs. In this endeavour, the evaluation of efficacy in animal models is often a go/no go decision assay in drug discovery. This important role relies on the capability of animal models to assess the disposition, toxicology and efficacy of drugs in a single test. Although the relative merits of each efficacy model of malaria as human surrogate have been extensively discussed, there are no critical analyses on the use of such models in current drug discovery. In this article, we intend to analyse how efficacy models are used to discover new antimalarial drugs. Our analysis indicates that testing drug efficacy is often the last assay in each discovery stage and the experimental designs utilized are not optimized to expedite decision-making and inform clinical development. In light of this analysis, we propose new ways to accelerate drug discovery using efficacy models.
- 21 June 2013
- Published by Cambridge University Press (CUP) in Parasitology
- Vol. 141 (1) , 93-103
Animal models of efficacy to accelerate drug discovery in malaria
SUMMARY: The emergence of resistance to artemisinins and the renewed efforts to eradicate malaria demand the urgent development of new drugs. In this endeavour, the evaluation of efficacy in animal models is often a go/no go decision assay in drug discovery. This important role relies on the capability of animal models to assess the disposition, toxicology and efficacy of drugs in a single test. Although the relative merits of each efficacy model of malaria as human surrogate have been extensively discussed, there are no critical analyses on the use of such models in current drug discovery. In this article, we intend to analyse how efficacy models are used to discover new antimalarial drugs. Our analysis indicates that testing drug efficacy is often the last assay in each discovery stage and the experimental designs utilized are not optimized to expedite decision-making and inform clinical development. In light of this analysis, we propose new ways to accelerate drug discovery using efficacy models.
- 1 May 2010
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (5) , 2262-2264
Fast Standardized Therapeutic-Efficacy Assay for Drug Discovery against Tuberculosis
Murine models of M ycobacterium tuberculosis infection are essential tools in drug discovery. Here we describe a fast standardized 9-day acute assay intended to measure the efficacy of drugs against M. tuberculosis growing in the lungs of immunocompetent mice. This assay is highly reproducible, allows good throughput, and was validated for drug lead optimization using isoniazid, rifampin, ethambutol, pyrazinamide, linezolid, and moxifloxacin.
- 1 May 2010
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (5) , 2262-2264
Fast Standardized Therapeutic-Efficacy Assay for Drug Discovery against Tuberculosis
Murine models of M ycobacterium tuberculosis infection are essential tools in drug discovery. Here we describe a fast standardized 9-day acute assay intended to measure the efficacy of drugs against M. tuberculosis growing in the lungs of immunocompetent mice. This assay is highly reproducible, allows good throughput, and was validated for drug lead optimization using isoniazid, rifampin, ethambutol, pyrazinamide, linezolid, and moxifloxacin.
- 1 October 2009
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (10) , 4533-4536
Improved Murine Model of Malaria UsingPlasmodium falciparumCompetent Strains and Non-Myelodepleted NOD-scid IL2RγnullMice Engrafted with Human Erythrocytes
Murine models ofPlasmodium falciparummalaria may become crucial tools in drug discovery. Here we show that non-myelodepleted NOD-scid IL2Rγnullmice engrafted with human erythrocytes support an infectious burden up to tenfold higher than that supported by engrafted NOD-scid β2microglobulinnullmice. The new model was validated for drug discovery and was used to assess the therapeutic efficacy of 4-pyridones, selective inhibitors ofP. falciparumcytochromebc1.
- 1 October 2009
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (10) , 4533-4536
Improved Murine Model of Malaria UsingPlasmodium falciparumCompetent Strains and Non-Myelodepleted NOD-scid IL2RγnullMice Engrafted with Human Erythrocytes
Murine models ofPlasmodium falciparummalaria may become crucial tools in drug discovery. Here we show that non-myelodepleted NOD-scid IL2Rγnullmice engrafted with human erythrocytes support an infectious burden up to tenfold higher than that supported by engrafted NOD-scid β2microglobulinnullmice. The new model was validated for drug discovery and was used to assess the therapeutic efficacy of 4-pyridones, selective inhibitors ofP. falciparumcytochromebc1.
- Open Access
- 10 September 2008
- Published by Wiley in Cytometry Part A
- Vol. 75A (3) , 225-235
Quantitative measurement of Plasmodium‐infected erythrocytes in murine models of malaria by flow cytometry using bidimensional assessment of SYTO‐16 fluorescence
Flow cytometry is a powerful tool for measuring parasitemias in murine malaria models used to test new antimalarials. Measurement of the emission of the nonpermeable nucleic acid dye YOYO‐1 (at 530 and 585 nm after excitation at 488 nm) allowed the unambiguous detection of low parasitemias (≥0.01%) but required prolonged fixation and permeabilization of the sample. Thus, we tested whether this issue could be overcome by use of the cell‐permeant dye SYTO‐16 with this same bidimensional method. Blood samples from CD1 mice infected with Plasmodium yoelii, Plasmodium vinckei, or Plasmodium chabaudi or from NODscidβ2m‐/‐ engrafted with human erythrocytes and infected with P. falciparum were stained with SYTO‐16 in the presence or absence of TER‐119 mAb (for engrafted mice) in 96‐well plate format and acquired in Trucount™ tubes. Bidimensional analysis with SYTO‐16 was quantitatively equivalent to YOYO‐1. Moreover, by combining SYTO‐16 with the use of TER‐119‐PE antimouse erythrocyte mAb and Trucount tubes, the measurement of the concentration of P. falciparum‐infected erythrocytes over a range of five orders of magnitude was achieved. Bidimensional analysis using SYTO‐16 can be used to accurately measure the concentration of Plasmodium spp.‐infected erythrocytes in mice without complex sample preparation. © 2008 International Society for Advancement of Cytometry
- 10 September 2008
- Published by Wiley in Cytometry Part A
- Vol. 75A (3) , 225-235
Open AccessQuantitative measurement of Plasmodium‐infected erythrocytes in murine models of malaria by flow cytometry using bidimensional assessment of SYTO‐16 fluorescence
Flow cytometry is a powerful tool for measuring parasitemias in murine malaria models used to test new antimalarials. Measurement of the emission of the nonpermeable nucleic acid dye YOYO‐1 (at 530 and 585 nm after excitation at 488 nm) allowed the unambiguous detection of low parasitemias (≥0.01%) but required prolonged fixation and permeabilization of the sample. Thus, we tested whether this issue could be overcome by use of the cell‐permeant dye SYTO‐16 with this same bidimensional method. Blood samples from CD1 mice infected with Plasmodium yoelii, Plasmodium vinckei, or Plasmodium chabaudi or from NODscidβ2m‐/‐ engrafted with human erythrocytes and infected with P. falciparum were stained with SYTO‐16 in the presence or absence of TER‐119 mAb (for engrafted mice) in 96‐well plate format and acquired in Trucount™ tubes. Bidimensional analysis with SYTO‐16 was quantitatively equivalent to YOYO‐1. Moreover, by combining SYTO‐16 with the use of TER‐119‐PE antimouse erythrocyte mAb and Trucount tubes, the measurement of the concentration of P. falciparum‐infected erythrocytes over a range of five orders of magnitude was achieved. Bidimensional analysis using SYTO‐16 can be used to accurately measure the concentration of Plasmodium spp.‐infected erythrocytes in mice without complex sample preparation. © 2008 International Society for Advancement of Cytometry
- Open Access
- 21 May 2008
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (5) , e2252
A Murine Model of falciparum-Malaria by In Vivo Selection of Competent Strains in Non-Myelodepleted Mice Engrafted with Human Erythrocytes
To counter the global threat caused by Plasmodium falciparum malaria, new drugs and vaccines are urgently needed. However, there are no practical animal models because P. falciparum infects human erythrocytes almost exclusively. Here we describe a reliable falciparum murine model of malaria by generating strains of P. falciparum in vivo that can infect immunodeficient mice engrafted with human erythrocytes. We infected NODscid/β2m−/− mice engrafted with human erythrocytes with P. falciparum obtained from in vitro cultures. After apparent clearance, we obtained isolates of P. falciparum able to grow in peripheral blood of engrafted NODscid/β2m−/− mice. Of the isolates obtained, we expanded in vivo and established the isolate Pf3D70087/N9 as a reference strain for model development. Pf3D70087/N9 caused productive persistent infections in 100% of engrafted mice infected intravenously. The infection caused a relative anemia due to selective elimination of human erythrocytes by a mechanism dependent on parasite density in peripheral blood. Using this model, we implemented and validated a reproducible assay of antimalarial activity useful for drug discovery. Thus, our results demonstrate that P. falciparum contains clones able to grow reproducibly in mice engrafted with human erythrocytes without the use of myeloablative methods.
- 21 May 2008
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (5) , e2252
Open AccessA Murine Model of falciparum-Malaria by In Vivo Selection of Competent Strains in Non-Myelodepleted Mice Engrafted with Human Erythrocytes
To counter the global threat caused by Plasmodium falciparum malaria, new drugs and vaccines are urgently needed. However, there are no practical animal models because P. falciparum infects human erythrocytes almost exclusively. Here we describe a reliable falciparum murine model of malaria by generating strains of P. falciparum in vivo that can infect immunodeficient mice engrafted with human erythrocytes. We infected NODscid/β2m−/− mice engrafted with human erythrocytes with P. falciparum obtained from in vitro cultures. After apparent clearance, we obtained isolates of P. falciparum able to grow in peripheral blood of engrafted NODscid/β2m−/− mice. Of the isolates obtained, we expanded in vivo and established the isolate Pf3D70087/N9 as a reference strain for model development. Pf3D70087/N9 caused productive persistent infections in 100% of engrafted mice infected intravenously. The infection caused a relative anemia due to selective elimination of human erythrocytes by a mechanism dependent on parasite density in peripheral blood. Using this model, we implemented and validated a reproducible assay of antimalarial activity useful for drug discovery. Thus, our results demonstrate that P. falciparum contains clones able to grow reproducibly in mice engrafted with human erythrocytes without the use of myeloablative methods.
- Open Access
- 4 August 2005
- Published by Wiley in Cytometry Part A
- Vol. 67A (1) , 27-36
Improvement of detection specificity of Plasmodium‐infected murine erythrocytes by flow cytometry using autofluorescence and YOYO‐1
Background: Microscopic analysis of blood smears is currently the most frequently used method to measure parasitemias in experiments of drug efficacy in murine models of malaria. However, it is subjective and labour intensive, which preclude its utilization in large‐scale evaluation programs. Flow cytometry is an alternative method, but due to the limited specificity achieved with the currently available techniques, it has not been widely used in murine models of malaria during preclinical evaluation. We describe a new flow cytometric method based on the differences of autofluorescence and DNA content measured after staining with YOYO‐1 that are observed in infected erythrocytes compared with noninfected erythrocytes.Methods: Samples of blood from Plasmodium yoelii–infected animals were fixed with glutaraldehyde, incubated with RNAase, and stained with YOYO‐1 in 96‐well plate format. After acquisition, erythrocytes gated in logarithmic side/scatter plots were analyzed in bidimensional FL‐2/YOYO‐1 plots in comparison with unidimensional YOYO‐1 analysis.Results: The infected erythrocytes showed a characteristic pattern of staining different from that of noninfected erythrocytes. In routine evaluation, the limit of sensitivity was 0.01% and the measurements of parasitemia were linear at parasitemias above 0.1%. Interestingly, using this approach, infected reticulocytes could be differentiated from infected normocytes.Conclusions: The method described is robust, increases the specificity and sensitivity of detection in routine testing, and is especially well suited for detection of low parasitemias in murine models of malaria.
- 4 August 2005
- Published by Wiley in Cytometry Part A
- Vol. 67A (1) , 27-36
Open AccessImprovement of detection specificity of Plasmodium‐infected murine erythrocytes by flow cytometry using autofluorescence and YOYO‐1
Background: Microscopic analysis of blood smears is currently the most frequently used method to measure parasitemias in experiments of drug efficacy in murine models of malaria. However, it is subjective and labour intensive, which preclude its utilization in large‐scale evaluation programs. Flow cytometry is an alternative method, but due to the limited specificity achieved with the currently available techniques, it has not been widely used in murine models of malaria during preclinical evaluation. We describe a new flow cytometric method based on the differences of autofluorescence and DNA content measured after staining with YOYO‐1 that are observed in infected erythrocytes compared with noninfected erythrocytes.Methods: Samples of blood from Plasmodium yoelii–infected animals were fixed with glutaraldehyde, incubated with RNAase, and stained with YOYO‐1 in 96‐well plate format. After acquisition, erythrocytes gated in logarithmic side/scatter plots were analyzed in bidimensional FL‐2/YOYO‐1 plots in comparison with unidimensional YOYO‐1 analysis.Results: The infected erythrocytes showed a characteristic pattern of staining different from that of noninfected erythrocytes. In routine evaluation, the limit of sensitivity was 0.01% and the measurements of parasitemia were linear at parasitemias above 0.1%. Interestingly, using this approach, infected reticulocytes could be differentiated from infected normocytes.Conclusions: The method described is robust, increases the specificity and sensitivity of detection in routine testing, and is especially well suited for detection of low parasitemias in murine models of malaria.